HypertensionMeta-analysis
Semaglutide and blood pressure: an individual patient data meta-analysis
- Individual patient data meta-analysis of randomised trials
Authors' conclusion
This IPD analysis of three large RCTs found blood pressure reductions with semaglutide in participants with hypertension that were similar to those seen in all trial participants.
Study context
- Population
- Participants of 3 randomized clinical trials (RCTs) of semaglutide 2.4 mg on body weight over 68 weeks, categorised by hypertension status
- Participants
- 3,136 participants · 3 RCTs
- Comparison
- Semaglutide 2.4 mg vs placebo
- Semaglutiden = 2,109
- Placebon = 1,027reference
- Outcome
- In-trial change in SBP
Pooled result
As reported in the abstract
Change in SBP, by hypertension category
Semaglutide vs PlaceboDifference, mmHg (95% CI)
overall
−4.95(−5.86 to −4.05)
HTN
−4.78(−5.97 to −3.59)
HTN130 (baseline SBP > 130 mmHg)
−4.93(−6.75 to −3.11)
HTN140 (baseline SBP >140 mmHg)
−4.09(−7.12 to −1.06)
RH (apparent resistant hypertension)
−3.16(−8.69-2.37)
Further pooled results
| Outcome | difference (95% CI) | |
|---|---|---|
| Anti-hypertensive treatment intensity score | −0.51 (−0.71 to −0.32) | |
| −1−0.500.5Difference (linear scale) |
Mediation of systolic blood pressure (SBP) reduction
- SBP reduction mediated substantially by weight loss
Original publication
Semaglutide and blood pressure: an individual patient data meta-analysis. Eur Heart J. Published 1 September 2024. doi:10.1093/eurheartj/ehae564
Summarised from the published abstract; every number is checked against it